抑郁障碍的生物节律和相关新药临床评价研究进展

被引：3

作者：

顾牛范 ^{[1
]}

李华芳 ^{[1
]}

陈兴时 ^{[2
]}

王勇 ^{[2
]}

机构：

[1] 上海交通大学医学院附属精神卫生中心国家新药临床药理基地

[2] 上海市精神卫生研究所神经生理室

来源：

神经病学与神经康复学杂志 | 2009年 / 6卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R749.4 [情感性精神病];

学科分类号：

100204 [神经病学];

摘要：

引用

页码：303 / 307

页数：5

共 18 条

[1]

The interaction between the internal clock and antidepressant efficacy.[J].Giorgio Racagni;Marco A. Riva;Maurizio Popoli.International Clinical Psychopharmacology.2007,

[2]

Cortisol circadian rhythm alterations in psychotic major depression [J].

Keller, Jennifer ;

Flores, Benjamin ;

Gomez, Rowena G. ;

Solvason, H. Brent ;

Kenna, Heather ;

Williams, Gordon H. ;

Schatzberg, Alan F. .

BIOLOGICAL PSYCHIATRY, 2006, 60 (03) :275-281

[3]

Melatonin in mood disorders [J].

Srinivasan, Venkataramanujan ;

Smits, Marcel ;

Spence, Warren ;

Lowe, Alan D. ;

Kayumov, Leonid ;

Pandi-Perumal, Seithikurippu R. ;

Parry, Barbara ;

Cardinali, Daniel P. .

WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, 2006, 7 (03) :138-151

[4]

Asymmetric Expression of Melatonin Receptor mRNA in Bilateral Paravertebral Muscles in Adolescent Idiopathic Scoliosis.[J].Dirk Uyttendaele;Peter H. Dangerfield;Liang Wu;Yong Qiu;Bin Wang;Yang Yu;Zhezang Zhu.Studies in Health Technology and Informatics.2006,

[5]

Phase-shifts of 24-h rhythms of hormonal release and body temperature following early evening administration of the melatonin agonist agomelatine in healthy older men [J].

Leproult, R ;

Van Onderbergen, A ;

L'Hermite-Balériaux, M ;

Van Cauter, E ;

Copinschi, G .

CLINICAL ENDOCRINOLOGY, 2005, 63 (03) :298-304

[6]

Molecular tools to study melatonin pathways and actions [J].

Boutin, JA ;

Audinot, V ;

Ferry, G ;

Delagrange, P .

TRENDS IN PHARMACOLOGICAL SCIENCES, 2005, 26 (08) :412-419

[7]

P.2.064 Efficacy of agomelatine versus venlafaxine on subjective sleep of patients with major depressive disorder.[J]..European Neuropsychopharmacology.2005, S3

[8]

Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT2C antagonist, in the treatment of major depressive disorder:: a placebo-controlled dose range study [J].